# SOLIDARITY Finland Plus Long-COVID

> **NCT05220280** · PHASE4 · UNKNOWN · sponsor: **Clinical Urology and Epidemiology Working Group** · enrollment: 400 (estimated)

## Conditions studied

- Covid19
- Coronavirus Disease 2019
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT05220280
- **Lead sponsor:** Clinical Urology and Epidemiology Working Group
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-06
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-05-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220280, "SOLIDARITY Finland Plus Long-COVID". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05220280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*